Rules-Based Medicine Commercializes New Toxicity Biomarker Panel in Conjunction with FDA, EMEA, C-Path and PSTC
For use in pre-clinical trials to evaluate early renal toxicity, new Rat Kidney MAP will aid in faster development of safer drugs
AUSTIN, TX (June 30, 2008) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has commercialized a new biomarker panel to aid pharmaceutical and biotech companies evaluate renal toxicity in rats for pre-clinical drug trials. RBM’s Rat Kidney MAP (multi-analyte profile) measures key biomarkers found in urine that can provide additional information about drug-induced damage to kidney cells, known as renal toxicity or nephrotoxicity.
Rules-Based Medicine and Psynova Neurotech to Co-Develop Blood Test for Diagnosis of Schizophrenia
Partnership gives RBM exclusive rights to market and sell diagnostic test worldwide
AUSTIN, TX (June 11, 2008) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory, announced today that it is partnering with Psynova Neurotech to co-develop and commercialize a blood test for the diagnosis of schizophrenia. RBM and Psynova will focus on the unmet clinical need for an objective and reliable diagnostic test to accelerate and optimize the treatment of schizophrenia. Under the terms of the agreement, the companies will collaborate on the validation, regulatory approval and manufacture of a diagnostic blood test for schizophrenia that will be sold worldwide exclusively by RBM.
Rules-Based Medicine Partners with EMD to Develop and Distribute Multi-Analyte Kits
Pharmaceutical, biotechnology and academic labs to gain access to the industry’s largest catalog of quantitative protein multiplex assays
AUSTIN, TX (December 10, 2007) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it is partnering with the Novagen brand of EMD Chemicals Inc. (EMD), a subsidiary of Merck KGaA (Merck) of Germany, to develop and distribute high-quality immunoassay products on the Luminex® xMAP® platform. Under the terms of the agreement, RBM is granting EMD/Merck exclusive distribution rights to the largest catalog of quantitative protein multiplex assays currently available.
Rules-Based Medicine Partners with EMD to Develop and Distribute Multi-Analyte Kits
Pharmaceutical, biotechnology and academic labs to gain access to the industry’s largest catalog of quantitative protein multiplex assays
AUSTIN, TX (December 10, 2007) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it is partnering with the Novagen brand of EMD Chemicals Inc. (EMD), a subsidiary of Merck KGaA (Merck) of Germany, to develop and distribute high-quality immunoassay products on the Luminex® xMAP® platform. Under the terms of the agreement, RBM is granting EMD/Merck exclusive distribution rights to the largest catalog of quantitative protein multiplex assays currently available.
Rules-Based Medicine Raises $25 Million in Series A Funding
Equity Group Investments leads round, joined by Cross Creek Capital and Stephens Capital Partners; Matt Zell named to Board of Directors
AUSTIN, TX (October 15, 2007) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory, announced today that it has raised $25 million in private financing. Equity Group Investments LLC (EGI), an investment fund founded by Sam Zell, led the Series A investment round. EGI is joined by Cross Creek Capital, the private equity affiliate of Wasatch Advisors, Inc. and Stephens Capital Partners. The financing will provide growth capital, debt repayment, and funding for acquisitions and investments to discover and validate biomarkers for medical diagnostics. In conjunction with the funding, RBM also announced that Matt Zell, managing director of EGI, has joined its Board of Directors.
Rules-Based Medicine Awarded $849,000 Grant by the National Institutes of Health
AUSTIN, Texas—(BUSINESS WIRE)—November 15, 2007—Rules-Based Medicine, Inc. (RBM) announced today that the National Institutes of Health has awarded RBM a "Fast-Track" grant for the development of a diagnostic test for neonatal sepsis. The grant, entitled "Biomarker Profiles for Early Diagnosis of Sepsis in Neonates," utilizes RBM’ s HumanMAP ® platform to characterize and validate a pattern of biomarkers that can detect early signs of infection in newborns. This project will be performed in collaboration with the University of New Mexico (UNM) in Albuquerque.
National Cancer Institute Awards $1.1 Million SBIR Contract to Rules-Based Medicine, Inc.
Goals of Funding are Earlier Detection and Better Characterization of Cancer
AUSTIN (October 10, 2007) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that the National Cancer Institute (NCI) has awarded the company a Phase I/Phase II "Fast-Track" Small Business Innovation Research (SBIR) Contract valued at $1,126,627. The contract will fund the development of 50 new quantitative, multiplexed immunoassays for cancer-related proteins to be added to the automated RBM Human Multi-Analyte Profile (HumanMAP®) platform. With the addition of these tests, RBM’s HumanMAP® will be expanded to more than 100 quantitative immunoassays for cancer biomarkers (as part of an existing panel of nearly 300 immunoassays) available for fast, sensitive, reproducible and cost-effective use by the worldwide community of cancer researchers.
Rules-Based Medicine Merges with EDI GmbH
Acquisition to benefit pharmaceutical, biotechnology and consumer products industries with comprehensive ex vivo biomarker testing platforms to aid pre-clinical and clinical research
AUSTIN, TX (October 9, 2007) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has acquired Experimentelle and Diagnostische Immunologie, GmbH, (EDI) in Reutlingen, Germany, an innovative developer of human organotypic (HOT) cell culture test systems. This transaction leverages the strong synergies between EDI’s HOT cultures and RBM’s Multi-Analyte Profiling (MAP) biomarker testing services. Researchers in the pharmaceutical, biotechnology and consumer products industries will benefit from these comprehensive ex vivo biomarker testing platforms, which will help bring safer products to market faster and at a lower cost. Terms of the agreement were not disclosed.
Rules-Based Medicine Awarded Phase II STTR Contract by U.S. Department of Defense
Austin, Texas, February, 2007 — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has been awarded a Phase II Small Business Technology Transfer (STTR) grant by the United States Department of Defense entitled "Rapid Assessment of Individual Soldier Operational Readiness."
Changing Game Plan for Protein Profiling
January 1, 2007 — Genetic Engineering News & Biotechnology. Volume 27, Number 1. “The Changing Game Plan for Protein Profiling”. Integrated approaches are becoming the standard paradigm for proteomic studies. The "Multiplex Protein Biomarker Profiling” subsection highlights RBM’s capabilities including analyte menu expansion strategy and technology advantages.
Rules-Based Medicine and Multiplex Biosciences Merge
Merger extends R&D capabilities and product expertise; expands customer base
AUSTIN (November 15, 2006) — Rules-Based Medicine, Inc. (RBM), the leading multiplexed biomarker testing laboratory for the life sciences industry, announced today that it has merged with Lake Placid, New York-based Multiplex Biosciences, Inc. to extend its research and development capability in multiplexed assay product development and expand its customer base.
|
Rules-Based Medicine, Inc. | 3300 Duval Road • Austin, TX 78759 • T: 866-RBM-MAPS • F: 512-835-4687 • E: info@rbmmaps.com |